Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

The "Man Van" reached almost 3,500 men, 85% of whom showed up for scheduled screening exams. Almost 100 prostate cancers were ...

Opens in a new tab or window SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to ...